Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Antizol

(Fomepizole)

Small molecule

UUS Department of Veterans Affairs

0

Indications

2

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

1

Patents

Clinical

Trials by Indication[1]

Acetaminophen1 trial

4-methylpyrazole and Acetaminophen Metabolism

Completed·UUniversity of Arizona·Phase 1·NCT03878693·6 enrolled

Intravenous1 trial

Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)

Completed· Takeda logo

Takeda··NCT02415712·147 enrolled

Regulatory

FDA Approval Timeline[3]

Dec 4, 1997

ANTIZOL

NDA NDA020696

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fomepizole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fomepizole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA020696). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Antizol. U.S. Food & Drug Administration.
[5]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUS Department of Veterans Affairs

Patent Landscape[4]

Patent Cliff

Jun 30, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7553863Jun 30, 2027

Related News